| Bioactivity | Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis[1][2]. |
| Invitro | Milademetan (DS-3032) can stabilize TP53 and selectively induce CDKNA1, BAX and MDM2 expression in neuroblastoma cells with wild-type TP53[3].Milademetan (DS-3032b) treatment enhances TP53 target gene expression and induces G1 cell cycle arrest, senescence and apoptosis[3].Milademetan (DS-3032b, 0-2000 nM) treatment selectively inhibits viability, proliferation and migration of neuroblastoma cells with wildtype TP53 independently of MYCN status[4]. Cell Viability Assay[4] Cell Line: |
| Name | Milademetan tosylate hydrate |
| CAS | 2095625-97-9 |
| Formula | C37H44Cl2FN5O8S |
| Molar Mass | 808.74 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
Milademetan tosylate hydrate
CAS: 2095625-97-9 F: C37H44Cl2FN5O8S W: 808.74
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.